International Journal of Clinical Case Reports 2024, Vol.14, No.3, 132-143 http://medscipublisher.com/index.php/ijccr 143 Naciute M., Niemi V., Kemp R., and Hook S., 2020, Lipid-encapsulated oral therapeutic peptide vaccines reduce tumour growth in an orthotopic mouse model of colorectal cancer, Eur J Pharm Biopharm, 152:183-192. https://doi.org/10.1016/j.ejpb.2020.04.020 Nelde A., Rammensee H., and Walz J., 2021, The peptide vaccine of the future, Molecular & Cellular Proteomics : MCP, 20: 100022. https://doi.org/10.1074/mcp.R120.002309 PMid:33583769 PMCid:PMC7950068 Obara W., Kanehira M., Katagiri T., Kato R., Kato Y., and Takata R., 2018, Present status and future perspective of peptide - based vaccine therapy for urological cancer, Cancer Science, 109: 550-559. https://doi.org/10.1111/cas.13506 PMid:29345737 PMCid:PMC5834812 Parmiani G., Russo V., Maccalli C., Parolini D., Rizzo N., and Maio M., 2014, Peptide-based vaccines for cancer therapy, Human Vaccines & Immunotherapeutics, 10: 3175-3178. https://doi.org/10.4161/hv.29418 PMid:25483658 PMCid:PMC4514143 Peres L., Luz F., Pultz B., Brigido P., Araújo R., Goulart L., and Silva M., 2015, Peptide vaccines in breast cancer: The immunological basis for clinical response., Biotechnology Advances, 33(8): 1868-1877. https://doi.org/10.1016/j.biotechadv.2015.10.013 Stephens A., Burgess-Brown N., and Jiang S., 2021, Beyond just peptide antigens: the complex world of peptide-based cancer vaccines, Frontiers in Immunology, 12: 696791. https://doi.org/10.3389/fimmu.2021.696791 PMid:34276688 PMCid:PMC8279810 Tardón M., Allard M., Dutoit V., Dietrich P., and Walker P., 2019, Peptides as cancer vaccines., Current opinion in pharmacology: 47: 20-26. https://doi.org/10.1016/j.coph.2019.01.007 PMid:30831470 Urbani F., Ferraresi V., Capone I., Macchia I., Palermo B., Nuzzo C., Torsello A., Pezzotti P., Giannarelli D., Pozzi A., Santaquilani M., Roazzi P., Bastucci S., Catricala C., Malfa A., Vercillo G., Gualtieri N., Buccione C., Castiello L., Cognetti F., Nisticò P., Belardelli F., Moschella F., and Proietti E., 2020, Clinical and Immunological Outcomes in High-Risk Resected Melanoma Patients Receiving Peptide-Based Vaccination and Interferon Alpha With or Without Dacarbazine Preconditioning: A Phase II Study, Frontiers in Oncology, 10: 202. https://doi.org/10.3389/fonc.2020.00202 PMid:32211314 PMCid:PMC7069350 Wylie B., Ong F., Belhoul-Fakir H., Priebatsch K., Bogdawa H., Stirnweiss A., Watt P., Cunningham P., Stone S., and Waithman J., 2021, Targeting cross-presentation as a route to improve the efficiency of peptide-based cancer vaccines, Cancers, 13(24): 6189. https://doi.org/10.3390/cancers13246189 PMid:34944809 PMCid:PMC8699136 Yang J., Zhang Q., Li K., Yin H., and Zheng J., 2015, Composite peptide-based vaccines for cancer immunotherapy (Review)., International Journal of Molecular Medicine, 35(1): 17-23. https://doi.org/10.3892/ijmm.2014.2000 Yoshimura K., Minami T., Nozawa M., Kimura T., Egawa S., Fujimoto H., Yamada A., Itoh K., and Uemura H., 2016, A phase 2 randomized controlled trial of personalized peptide vaccine immunotherapy with low-dose dexamethasone versus dexamethasone alone in chemotherapy-naive castration-resistant prostate cancer, European Urology, 70(1): 35-41. https://doi.org/10.1016/j.eururo.2015.12.050 Zamani P., Teymouri M., Nikpoor A., Navashenaq J., Gholizadeh Z., Darban S., and Jaafari M., 2020, Nanoliposomal vaccine containing long multi-epitope peptide E75-AE36 pulsed PADRE-induced effective immune response in mice TUBO model of breast cancer., European Journal of Cancer, 129: 80-96. https://doi.org/10.1016/j.ejca.2020.01.010 PMid:32145473
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==